News Sentiment

ELV sentiment intelligence

Elevance Health Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 66 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Healthcare Plans Read-through group
Latest close 416.23 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

75/100 classification confidence.

Company focus 66

directly relevant articles

Source quality 9

high-authority source matches

Trend context Trend active

-0.4% over one week, +3.0% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

Guggenheim Adjusts Price Target on Elevance Health to $455 From $399, Maintains Buy Rating

Market Reaction

Balanced read

50/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 75/100 classification
One-week reaction -0.4% Price digesting
Trend fit Trend active 3.0% over four weeks
Fair value 2.0% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 31
Negative 12

Relevance

Why the article matched

Direct first
Direct company coverage 66
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
MT Newswires 6
simplywall.st 6
Stock Titan 6
Market source 5
Investing.com 3
TradingView 3
Quartr 2
GuruFocus 2

Event Lens

What the news is about

Classified themes
Earnings 29
Market update 21
Analyst action 9
Guidance 4
Deals and strategy 2
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 66
Quartr Direct company coverage

Elevance Health (ELV) Q2 2025 earnings summary

Elevance Health reported Q2 2025 operating revenue of $49.4 billion, a 14.3% year-over-year increase, driven by higher premium yields and Medicare Advantage growth, but net income decreased by 24.2% to $1.74 billion due to elevated medical costs. The company revised its full-year

Tone
Negative 38/100
Event
Earnings
Published
16 Jul 2026 00:08
Source
Quartr
Quartr Direct company coverage

Elevance Health (ELV) Q3 2025 earnings summary

Elevance Health reported strong Q3 2025 results with operating revenue up 12% year-over-year to $50.1 billion and diluted EPS of $5.32. Despite a slight decline in medical membership, the company returned $3.3 billion to shareholders year-to-date and reaffirmed its full-year 2025

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 21:08
Source
Quartr
Investing.com Direct company coverage

Agilon health stock hits 52-week high at 126.0 USD

Agilon Health Inc. stock reached a 52-week high of $125.71, currently trading at $125.66, reflecting a year-to-date return of 612% and a one-year gain of 123%. Despite trading with high price volatility, InvestingPro analysis suggests the stock remains undervalued relative to its

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 19:45
Source
Investing.com
MarketWatch Direct company coverage

Elevance Health Inc. stock underperforms Wednesday when compared to competitors

Shares of Elevance Health Inc. (ELV) fell by 8.54% on Wednesday, closing at $390.33, despite a positive trading session for the broader stock market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains, but Elevance Health's stock performance snapped a two-day w

Tone
Negative 29/100
Event
Market update
Published
15 Jul 2026 16:30
Source
MarketWatch
Stock Titan Direct company coverage

Elevance Health (NYSE: ELV) logs $1,463M Q2 2026 shareholder profit

Elevance Health reported Q2 2026 revenues of $50,474 million, up slightly from the previous year, but shareholder net income declined to $1,463 million due to expenses growing faster than revenue. Diluted EPS for the quarter was $6.71, down from $7.72. The company also announced

Tone
Negative 40/100
Event
Earnings
Published
15 Jul 2026 15:28
Source
Stock Titan
TradingView Direct company coverage

Elevance Health, Inc. Q2 2026: Revenue $50.47B, EPS $6.71— 10-Q Summary

Elevance Health, Inc. reported its second-quarter 2026 results, showing total revenue of $50.47 billion, a modest increase year-over-year, while diluted EPS declined to $6.71. The company experienced an increase in operating revenue due to premium rate adjustments and growth in C

Tone
Negative 36/100
Event
Earnings
Published
15 Jul 2026 15:08
Source
TradingView
Morningstar Direct company coverage

Elevance Is Focused on Improving Margins While Facing Near-Term Challenges

Elevance Health, a major licensee of the Blue Cross Blue Shield brand in 14 states, is working to improve its margins despite immediate challenges. The company holds a strong market position, insuring about one-third of the population in its licensed states, which aids in reimbur

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 14:37
Source
Morningstar
Benzinga Direct company coverage

Why Is Elevance Health Stock Sinking Wednesday? - Elevance Health (NYSE:ELV)

Elevance Health's stock is sinking despite beating Q2 earnings estimates and raising full-year guidance. Investors were reportedly underwhelmed as the guidance increase was smaller than the quarterly earnings beat, leading to a broader selloff among managed-care insurers. Elevate

Tone
Negative 29/100
Event
Earnings
Published
15 Jul 2026 14:22
Source
Benzinga
InsuranceNewsNet Direct company coverage

CVS Health Risk Factors: Key Regulatory, PBM, Insurance, and Pharmacy Risks

CVS Health faces significant risks across its diversified healthcare operations, including regulatory pressures on PBMs and pharmacies, medical cost volatility in its insurance segment (Aetna), and execution challenges from integration and acquisitions. The company's earnings sta

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 Jul 2026 14:07
Source
InsuranceNewsNet
Seeking Alpha Direct company coverage

Quanterix wins coverage for Alzheimer’s test (QTRX:NASDAQ)

Quanterix Corporation saw a ~3% increase in premarket trading after announcing that its Alzheimer’s test, LucentAD Complete, will be covered by Elevance Health’s Anthem Blue Cross and Blue Shield health plans starting this month. This coverage is expected to expand access to the

Tone
Positive 67/100
Event
Market update
Published
15 Jul 2026 12:40
Source
Seeking Alpha